Aquavit Files Investigation of New Drug for New Botulinum Toxin
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Tag: Aquavit Pharmaceuticals
All
Popular
All
LatestSorry, No Posts Found
All
Latest
Allergan Wins First Approval for Short-Acting Neurotoxin in Canada
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
